Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Blocking of a drug as a treatment for primary progressive multiple sclerosis (PPMS), making it unavailable for use by the UK’s National Health Service (NHS), is being challenged by the country’s MS Society. And it has coupled its opposition with a call to arms – inviting everyone to #SpeakupforMS. Holly, from the society’s campaigns community, … Continue reading Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Now Ocrevus blocked from health service in Scotland

Hot on the heels of NICE rejecting Ocrevus (ocrelizumab) as a treatment of PPMS by the National Health Service (NHS) in England, it has been blocked as a therapy for relapsing MS in Scotland. The Scottish Medicines Consortium (SMC) says it does not consider ocrelizumab to be cost effective for the NHS in Scotland  as a treatment … Continue reading Now Ocrevus blocked from health service in Scotland

Ocrevus blocked again, this time for PPMS, as not cost-effective

  So, news came out last week that the UK’s National Health Service will not be providing Ocrevus for treating primary progressive MS (PPMS) in England*. But, panic not, the decision is far from being set in stone. Why is this? Because the decision by the National Institute for Health and Care Excellence, (NICE), was … Continue reading Ocrevus blocked again, this time for PPMS, as not cost-effective

Threat to three DMTs removed after manufacturers cut prices

Manufacturers of three relapsing multiple sclerosis drugs have cut prices to remain available to Britain's National Health Service (NHS). They are all diseases modifying therapies (DMTs). In January, I brought you news that five such drugs were under threat, having been found to be not cost-effective as long-term therapy options. In a draft recommendation from … Continue reading Threat to three DMTs removed after manufacturers cut prices